Thread and Amazon Web Services (AWS) are modernising clinical research with the launch of cloud-based, AI-driven decentralised clinical trials technology.

The latest Thread platform, fuelled by automation and machine learning, is said to deliver more efficient, comprehensive and inclusive clinical studies on a global scale.

Thread is a technology and consulting service provider enabling electronic clinical outcome assessments and decentralised clinical trials (DCTs). It is collaborating with AWS to launch enhancements to its platform powered by enterprise-scale automation and built-in AI-driven technologies.

These DCT technology features will serve as the backbone for modern clinical research by enabling faster, more efficient clinical trials while improving access for research participants with higher quality data capture across the life cycle of a study.

Thread is working with AWS professional services experts to design a machine-learning architecture and AI models to automate processes. The cloud-enabled platform features should accelerate clinical research by reducing inefficiencies in real-time data capture, auto-populating data workflows that are completed manually today.

“Our technology innovations are revolutionising today’s clinical research by helping our customers to design, operate and scale modern clinical trial approaches,” said John Reites, CEO of Thread. “In collaboration with Amazon Web Services, we are further scaling our DCT platform with next-level automation, AI and ML offerings, and optimised features focused to meet the evolving needs of our customers, research sites, and participants.”

Dan Sheeran, general manager of AWS healthcare and life sciences, added: “With AWS powering its technology platform, Thread can deliver timely, relevant data that help researchers design more efficient clinical trials, in turn advancing precision medicine. The breadth and depth of AWS’s machine-learning and cloud capabilities will help support Thread teams as they work to automate processes, reduce inefficiencies, and monitor and support clinical trials. We’re proud to work with Thread and lend our deep domain expertise to assist in developing a platform that has the potential to reduce the time it takes to bring innovative medicines to patients globally.”

The DCT platform should:

• Accelerate the ability to offer and initiate co-created and configured trials by reducing the start-up time to onboard users by up to 30%.
• Help users eliminate inefficiencies by over 30% and achieve up to 25% cost savings when pre-completing data, reducing data capture and removing source data verification.
• Provide a more comprehensive view of participant data across the entirety of the study with enhanced security, AI support and operational controls.
• Allow users to monitor more precisely and support study success by providing richer data in real time, including real-time grades on study performance.

“By combining Thread’s advanced DCT platform with the security, scale and agility of AWS’s cloud and machine-learning technology expertise, we are empowering our customers to automate data capture and storage and at the same time providing predictive forecasts to better run studies and decrease the time it takes to conduct research.” said Scott Pearson, chief product officer at Thread. “This is the future of modern clinical research.”

Thread is a decentralised clinical trials technology and consulting service provider, helping biopharma and CROs decentralise clinical research and enable electronic clinical outcome assessments for sites, participants, caregivers and home health professionals.